Proactive Investors - Run By Investors For Investors
Why invest in SCLP?
Scancell Holdings PLC: DEEP DIVE
OVERVIEW

Scancell exploring new frontiers in cancer research

Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
lab worker
OVERVIEW: SCLP The Big Picture
The company has four lead products in development
  • Developing innovative cancer immunotherapies
  • Four lead products in development
  • Phase II and phase I/II studies in preparation targeting multiple cancer indications

What the company does

AIM-listed Scancell Holdings PLC (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing promise – they are the ImmunoBody and Moditope platforms. The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2. It is also developing MODI-1 and MODI-2 from the Moditope platform.

Recent time-line 

In April the firm said it was to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug within weeks, after receiving approval from regulators. The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s blockbuster checkpoint inhibitor, Keytruda.

The UK arm of the trial is scheduled to get underway before the end of June, and the Scancell team are working to secure approvals from US regulators so trials can also start across the pond. Last October, the US Food and Drug Administration (FDA) requested some more information around TriGrid – a delivery system developed by a third party – before granting SCIB1 investigational new drug status.

In May, Sancell and cancer Cancer Research UK (CRUK) announced further progress with Scancell's SCIB2 cancer immunotherapy vaccine. Pre-clinical studies have demonstrated that the administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival.

Inflexion points

The company expects to generate meaningful clinical data in the next two years from all four of its drug candidates (see below).

 

In recent updates investors have been told CRUK is planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.

And a planned phase I/II clinical study is of MODI-1 is expected to begin in the second half.

View full SCLP profile View Profile

Scancell Holdings PLC Timeline

Related Articles

technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
man with erectile dysfunction
Mon
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use